Strategic Partnerships TruDiagnostic has active and high-profile partnerships with Yale Corporation and L’Oréal, plus collaborations with Longevity Ltd. and other industry players, indicating strong interest from reputable brands in epigenetic testing and longevity. Target potential sales opportunities by exploring expanded co-development, validation studies, and white-label offerings with consumer brands and cosmetic/biotech leaders.

Clinical and Consumer Reach The company serves both clinical practitioners and direct-to-consumer markets, suggesting sales opportunities in scalable test kits, clinician education programs, and CRM-enabled patient engagement tools to drive adoption across healthcare networks and consumer platforms.

Financial Momentum Revenue is in the multi-year growth range and recent funding includes a NIH-related grant, signaling credibility and ongoing capital for expansion. Leverage financial health to propose enterprise-scale pilots, reimbursement strategy support, and scalable data infrastructure partnerships.

Research and Validation Active participation in studies and recognition for Horvath clock tests position TruDiagnostic as a leader in validated epigenetic analytics. Upsell advanced assay development, cross-validation services, and access to longitudinal datasets for pharma, biotech, and wellness brands focusing on aging and disease prevention.

Technology and Platform Utilizes cloud, AI collaboration (with Yale) and robust tech stack including AWS, Google Cloud, Salesforce, and Webflow, indicating opportunities to offer integration services, data interoperability solutions, and enterprise analytics dashboards for healthcare providers and corporate wellness programs.